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Abstract 
Background: There is growing evidence that sleep duration and quality may be associated 
with cardiovascular harm and mortality. 
Methods and Results: We conducted a systematic review, meta-analysis and spline analysis 
of prospective cohort studies which evaluate the association between sleep duration and 
quality, and cardiovascular outcomes.  We searched MEDLINE and EMBASE for these 
studies and extracted data from identified studies. We employed linear and non-linear dose-
response meta-analysis models and used DerSimonian-Laird random-effects meta-analysis 
models of risk ratios, with inverse variance weighting, and the I2 statistic to quantify 
heterogeneity. 74 studies including 3,340,684 participants with 164,600 deaths among 
1,447,093 participants who reported death events. Findings were broadly similar across both 
linear and non-linear dose response models in 30 studies with >1,000,000 participants, and 
we report results from the linear model. Self-reported duration of sleep beyond 8 hours was 
associated with a moderate increased risk of all-cause mortality, with RR 1.14(1.05-1.25) for 
9 hours, RR 1.30(1.19-1.42) for 10 hours and RR 1.47(1.33-1.64) for 11 hours. No significant 
difference was identified for periods of self-reported sleep below 7 hours, while similar 
patterns were observed for stroke and cardiovascular disease mortality.  Subjective poor sleep 
quality was associated with coronary heart disease (RR 1.44 95%CI 1.09-1.90) but no 
difference in mortality and other outcomes. 
Conclusions: Divergence from the recommended 7 to 8 hours of sleep is associated with a 
higher risk of mortality and cardiovascular events. Longer duration of sleep may be more 
associated with adverse outcomes compared with shorter sleep durations.  
Keywords: meta-analysis; coronary artery disease; cardiac risk factors and prevention 
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Clinical Perspective 
What is new? 
• In this meta-analysis of 74 studies representing over 3 million participants, we found 
that a J-shaped relationship between sleep duration and mortality and incident 
cardiovascular disease. 
• Duration of sleep beyond 8 hours of sleep was associated with increased risk of 
mortality, with RR 1.14 (1.05-1.25) for 9 hours, RR 1.30 (1.19-1.42) for 10 hours and 
RR 1.47 (1.33-1.64) for 11 hours. 
• No significant effect was identified for periods of sleep below 7 hours, while similar 
patterns were observed for stroke and cardiovascular disease mortality.  
• Subjective poor sleep quality was associated with a significant increase in coronary 
heart disease (RR 1.44 95%CI 1.09-1.90) but not for mortality or any other outcomes. 
What are the clinical implications? 
• Our study suggests that abnormal sleep is a marker of elevated cardiovascular risk – 
and greater attention in consultations with patients to ask, and give advice about 
optimising the duration and quality of sleep may help reduce the burden of 
cardiovascular disease.  
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Introduction 
 Cardiovascular disease causes over 787,000 deaths in the United States.(1) Whilst 
sleep duration is generally not considered a traditional risk factor for cardiovascular disease, 
growing evidence supports its association with cardiovascular risk factors(2-7) and 
disease,(8-11) and quality of sleep appears to contribute to cardiovascular risk.(10,12) Yet, 
current guidelines for the risk reduction of cardiovascular disease make limited 
recommendations about the quality or duration of sleep.(13,14) 
 The National Sleep Foundation recommends 7-9 hours of sleep for people age 26-64 
years, 7-8 hours of sleep for people age ≥65 years,(14) and the Center for Disease Control 
and Prevention has similar recommendations for adults.(15) Whether adults sleep the 
recommended hours is influenced by cultural, social, psychological, behavioral, 
pathophysiological and environmental influences.(16,17) Sleep duration may be reduced 
because of irregular working and shift-work patterns, and round the clock availability of 
commodities of modern society.(18) However, guidelines makes no specific reference with 
regards to sleeping beyond the recommended limit. Long sleep duration may be associated 
with obstructive sleep apnea, heart disease, failing health (19) or may represent a symptom of 
early ‘latent’ disease prior to a formal diagnosis.(20)  
 While previous reviews have evaluated sleep duration and mortality and 
cardiovascular outcomes, (10,16) these reviews have not quantified the cardiovascular risk 
associated with each hour deviation below or above the recommended sleep duration. In 
addition, none of the previous reviews assessed the influence of sleep quality.(10,16) Thus, 
we conducted a systematic review and meta-analysis of the impact of sleep duration and 
quality on cardiovascular disease and mortality.  
 
  
6 
 
Methods 
The data, analytic methods, and study materials will not be made available to other 
researchers for purposes of reproducing the results or replicating the procedure. 
 The full methods including detailed eligibility criteria, search strategy, data selection, 
extraction and analysis are reported in Appendix 1.  The manuscript is prepared according the 
guidance of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement 
(Supplementary Material). 
Eligibility criteria 
 We selected prospective cohort studies that reported participants who quantified their 
duration of sleep or quality of sleep, and their association with subsequent cardiovascular 
disease and mortality.  The primary outcome was all-cause mortality and secondary outcomes 
were cardiovascular disease and mortality. 
Search strategy 
 We searched Medline and Embase using Ovid SP (from inception to the end of 
October 2015) using the search terms in Appendix 1.   
Study selection and data extraction 
 Two reviewers (CSK and AM) checked all titles and abstracts for studies that could 
potentially meet the inclusion criteria.  Data extraction and risk of bias assessment was 
performed independently by at least two reviewers (CSK, GK or MG).  Publication bias was 
assessed using funnel plots. 
Data analysis 
We used Stata version 14 to perform regression analysis with random-effects dose-
response meta-analysis models to estimate the association between hours of sleep and adverse 
outcomes, using 7 hours of sleep as the reference category. The linear model represents the 
primary analysis and the cubic model was included as a supplemental analysis. 
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Conventional random effects meta-analysis was performed as a secondary analysis 
using RevMan 5.3 (Nordic Cochrane Centre).  We decided to use random-effects models 
since they are more conservative compared to fixed-effect models, in the presence of any 
heterogeneity. Statistical heterogeneity was assessed using the I2 statistic.  The details of the 
main and sensitivity analyses are described in Appendix 1. We also performed analysis of 
sleep quality (Supplementary Table 1) in relation to mortality and cardiovascular outcomes. 
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Results 
Description of included studies 
 A total of 74 studies met the inclusion criteria; the process of study selection is shown 
in Figure 1.(8,9,11,12,21-90)  The study design and participant characteristics are shown in 
Table 1. The included studies were dated 1970-2017, which represented 3,340,684 
participants. Among studies which reported crude events there were 242,240 all-cause deaths 
in 2,564,029 participants from 44 studies (9.4%), 5,435 coronary heart disease deaths in 
741,695 participants from 7 studies (0.7%), 6,380 stroke deaths in 374,728 participants from 
5 studies (1.7%), 32,988 cardiovascular deaths in 759,939 participants from 14 studies 
(4.3%), 32,084 coronary heart disease events in 540,538 participants from 14 studies (5.9%), 
14,946 stroke events in 525,620 participants from 11 studies (2.8%) and 4,160 cardiovascular 
disease events in 97,832 participants from 6 studies (4.3%).  Supplementary Table 2 shows 
the prevalence of cardiovascular disease and cardiovascular risk factor profiles for each 
cohort.  
 
Quality assessment of included studies 
 The quality assessment is shown in Supplementary Table 3. The studies used 
questionnaires or direct questioning to ascertain information about sleep quality or sleep 
duration. Methods used to estimate outcomes included population registries, death 
certification, questionnaires, review of medical records or patient through interview or 
telephone call. Most studies adjusted for potential confounders, but the factors adjusted for 
varied across studies. Loss to follow up was unclear in 30 studies and 12 studies had 10% or 
more loss to follow up or missing data. The study reference group and studies included for 
each analysis is shown in Supplementary Table 4. 
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Sleep duration and all-cause mortality 
 The numeric results of the analyses are shown in Table 2 and Table 3. For the spline 
analysis a total of 30 studies (11,21,23,25,26,29,32,33,36,41,44,47-49,52,55-
57,60,64,66,68,70,71,79,80,84,86-88 ) reported data that could be used for the all-cause 
mortality analysis. When spline analysis was applied using linear model, incremental 
deviation below 7 hours of self-reported sleep was not associated with increased risk of all-
cause mortality but sleep durations longer than 8 hours were associated with increased risk of 
all-cause mortality (Figure 2). The cubic spline analysis model is shown in Supplementary 
Figure 1. 
 The pooled risk of all-cause mortality for the entire cohort (Figure 2, Supplementary 
Figure 2) and the subgroup of men and women only are shown in Supplementary Table 4.  
There were a total of 39 studies included in the analysis (11,21,23,25-27,29,32-34,36,39-
41,44,46-49,51-54,56,57,61,64,66,68,70-72,77,79,80,84,86-88). The funnel plot for sleep 
duration and mortality did not suggest there was publication bias. Deviation from self-
reported sleep duration of 7 or 8 hours appeared to be associated with all-cause mortality, 
where longer sleep durations are associated with greater mortality compared to small 
increases for shorter durations. The similar J-shaped relationship was observed for the 
subgroup of men and women.   
 
Sleep duration and coronary heart disease mortality and coronary heart disease 
 A total of 5(37,47,49,75,78) and 12(8,12,22,24,38,42,58,63,69,74,83,84) studies were 
included in spline analysis for coronary heart disease mortality and coronary heart disease 
respectively. Linear spline analysis failed to demonstrate any significant difference for both 
outcomes for self-reported shorter and longer sleep durations (Figure 3, cubic model in 
Supplementary Figure 1). 
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 For the meta-analysis there were 7 studies (37,47,49,51,61,75,78) (Supplementary 
Figure 3) and 15 studies (8,12,22,24,38,40,42,58,59,63,69,74,81,83,84) (Supplementary 
Figure 4) for coronary heart disease mortality and coronary heart disease respectively. While 
there were fewer studies, a similar J-shaped pattern was observed where there was greater 
risk of coronary heart disease mortality and events with incremental deviation from the 
reference 7 to 8 hours of self-reported sleep (a modest increase for 6 hours and greater 
increase for ≤5 hours) (Supplementary Table 5). The funnel plot for self-reported sleep 
duration and coronary heart disease mortality suggested possible publication bias while for 
coronary heart disease the plot did not suggest there was publication bias.   
 
Sleep duration and stroke mortality and stroke 
 Linear spline analysis for stroke mortality and stroke included 3 (47,49,65) and 9 
(8,22,31,42,43,50,69,76,83) studies, respectively. There was no difference in stroke events 
associated with self-reported sleep duration shorter or longer than 7 hours but a moderate 
increase in stroke mortality if sleep duration was greater than 7 hours (Figure 3, cubic model 
in Supplementary Figure 1). 
 Meta-analysis of 5 studies (27,47,49,51,65) were included in the analysis of stroke 
mortality (Supplementary Figure 5). For stroke events, there were 13 studies 
(8,9,22,31,42,43,59,69,73,76,81,83) The funnel plot for sleep duration and stroke mortality 
did not suggest publication bias. For stroke mortality, there appeared to be no difference in 
events with self-reported sleep duration below 7 hours but significant and moderate increase 
in events with longer sleep duration beyond 8 hours (Supplementary Figure 5).  However, for 
stroke events the increase in event rates are preserved for both sleep duration shorter than 7 
hours (modest for 6 hours and a greater increase for ≤5 hours) and a moderate increase for 
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longer than 8 hours (Supplementary Figure 6).  The funnel plot for sleep duration and stroke 
did not suggest publication bias.   
 
Sleep duration and cardiovascular mortality and cardiovascular disease 
 Spline analysis using linear models did not shown any difference in events with 
shorter duration than 7 hours for both cardiovascular mortality (8 studies) 
(11,25,44,47,49,71,87,88) and cardiovascular disease (7 studies) (8,12,22,33,38,42,74). 
However, longer self-reported sleep duration beyond 7 hours appeared to be associated with a 
moderate increase in greater stroke mortality (Cubic model shown in Supplementary Figure 
1). 
 There were 16 studies (8,11,25-27,32,44,47,49,51,54,57,66,71,87,88) (Supplementary 
Figure 7), which evaluated cardiovascular disease mortality and 8 studies 
(8,12,22,28,33,38,42,74) (Supplementary Figure 8) which evaluated cardiovascular disease 
events. The J-shaped pattern was observed for self-reported sleep duration and cardiovascular 
disease mortality but this was not the case for cardiovascular disease events but there were 
fewer studies in the event analysis.  The funnel plot for sleep duration and cardiovascular 
disease mortality and cardiovascular disease did not suggest publication bias. Incremental 
decrease in hours of sleep was associated with significant increase in mortality 
(Supplementary Table 5).   
 
Sleep quality and mortality and adverse cardiovascular outcomes 
 A total of 17 studies (8,11,12,30,32,35,38,43,45,46,52,61-63,68,71,78,82) were 
included in the analysis of subjective sleep quality and adverse outcomes (Supplementary 
Figure 9, Supplementary Table 4). For all-cause mortality there were 12,652 deaths among 
73,702 participants from 10 studies and the pooled results suggest that poor subjective quality 
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of sleep was not associated with significant increase in mortality (RR 1.03 95%CI 0.93-1.14).  
Poor sleep quality was associated with a significant and moderate increase in coronary heart 
disease (RR 1.44 95% CI 1.09-1.90) but not for any other outcomes. The funnel plot for sleep 
quality did not suggest publication bias.   
 
Sensitivity analysis excluding studies which did not exclude baseline cardiovascular disease, 
adjust for cardiac risk factors and adjusted for snoring or obstructive sleep apnea 
 Sensitivity analysis was performed on the meta-analysis data (Supplementary Table 
6).  After exclusion of studies that included participants with baseline cardiovascular disease, 
there was significant increase in all-cause mortality with longer and shorter self-reported 
hours of sleep (small for 6 hours, modest for 5 and 9 hours and moderate for 4 and 10 hours) 
and moderate increase in cardiovascular disease mortality and stroke mortality with longer 
hours of sleep. Similar observations were found for studies that adjusted for cardiovascular 
risk factors.  For the analysis of coronary heart disease and stroke, there were significant and 
moderate increases in events when baseline cardiovascular disease was excluded with 5 hours 
duration of sleep.  For the adjustments for obstructive sleep apnea analysis some of the results 
were no longer statistically significant because there were fewer studies.   
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Discussion 
 In this meta-analysis of 60 studies representing over 3 million participants, we 
observed that divergence from the recommended 7 to 8 hours of sleep was significantly 
associated with a moderate increase in mortality and incident cardiovascular disease.  We 
observed a J-shaped relationship between sleep duration and mortality and incident adverse 
cardiovascular events was observed. When spline analysis was applied to evaluate the 
incremental association of sleep duration and adverse events our results suggest that longer 
than the recommended duration of 7-8 hours of sleep may be associated with a moderate 
degree of harm, compared with those who slept for durations shorter than that recommended.   
 Our study provides evidence that may contribute to important clinical and public 
health messages.  Firstly, we observed through spline analysis a more precise estimation of 
the risk gradient of cardiovascular disease and mortality on the greater side of the 
recommended 7 to 8 hours of sleep compared to existing studies. Secondly, deviations in 
sleep duration and quality may be a non-specific marker for increased cardiovascular risk that 
might warrant determination of cardiovascular risk.  In particular, clinicians may need to be 
aware that the risk gradient appears to be steeper for long sleep duration compared to short 
duration so individuals with excessive sleeping patterns may warrant further clinical 
assessment.  Thirdly, we provide updated evidence that supports the J-shaped relationship 
where longer sleep is associated with significant higher mortality and cardiovascular disease 
and further the knowledge by highlighting that excess sleep is possibly associated with a 
greater likelihood of harm than less sleep with spline analysis.  In addition, we found that 
sleep quality emerged as an important risk factor for coronary heart disease, so clinicians 
should consider non-restorative sleep (or ‘waking up unrefreshed`) during patient assessment.  
Finally, our study highlights current evidence that sleep may be an important factor for 
individuals who wish to adopt a healthier lifestyle – our findings support public health 
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campaigns promoting good sleep practices and behaviors, and the importance of the clinician 
discussing sleep in primary care consultations.  
 St-Onge et al, recently published a scientific statement on behalf of the American 
Heart Association.(91)  There review surveyed the literature and found that sleep duration, 
mostly short sleep and sleep disorders are related to adverse cardiometabolic risk such as 
obesity, hypertension, type 2 diabetes and cardiovascular disease.  Unlike their review, we 
focused on mortality and cardiovascular disease and quantitatively pooled the impact of 
individual hours of sleep duration and these events.  We were able to show with meta-
regression that the association of short sleep duration and adverse events was lost but the 
association of long sleep duration and adverse events still persists.  It is possible that the 
adverse outcomes associated with short sleep duration may be manifested through the risk 
factors described by St-Onge's review.  Our findings support the clinical recommendations of 
the American Heart Association in which sleep behaviors should be addressed to promote 
cardiac health, and public health campaigns addressing sleep behavior should include explicit 
guidelines for adequate sleep. 
 Our meta-analysis results show a possible increase in mortality with both long and 
short duration of sleep relative to 7 or 8 hours but after spline analysis there is no difference 
in mortality for patients with shorter sleep duration. The spline regression is the gold standard 
for meta-regression for non-linear relationships to model exposures and outcomes. We further 
used this method to perform analysis on the subgroups studies that had more complete 
reporting that includes crude event rates. 
 The exact mechanisms that underlie the association between sleep and cardiovascular 
disease and mortality are not fully understood. Short sleep duration has been shown to 
increase levels of leptin and ghrelin (92,93) which leads to increased appetite, caloric intake, 
reduce energy expenditure and facilitates the development of obesity(80) and impaired 
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glycemic control.(94) Cortisol also increases with reduced sleep and altered growth hormone 
metabolism may increase cardiovascular risk.(95) Low grade inflammation occurs with 
reduced sleep which may be associated with cardiovascular disease and cancer.  Long sleep 
duration may be associated with an increased risk of cardiovascular disease because of an 
adverse cardiometabolic risk factor profile or prevalent comorbidities that lead to fatigue such 
as chronic inflammatory disorders and anemia. Depressive symptoms, low socioeconomic 
status, unemployment, low physical activity are also associated with long sleep duration 
which may confound the association of long sleep with morbidity and mortality.(96) 
An important consideration in the temporal relationship between sleep and adverse 
outcomes is the potential influence of cardiovascular risk factors.  For example, a Japanese 
study observed that sleep disturbances was associated with a higher risk of later onset of type 
2 diabetes.(97) In addition, it is unclear whether abnormal sleep is a marker of undiagnosed 
prevalent cardiovascular diseases or of early/latent disease that subsequently manifests in 
adverse cardiovascular outcomes and death. Some studies have attempted to reduce the effect 
of baseline prevalent cardiovascular disease by excluding patients with these conditions while 
other studies adjusted for these factors. Despite our sensitivity analysis considering exclusion 
and adjustments, there may still be residual confounding as there may be undiagnosed or 
latent disease or risk factors as some of these population-based studies do investigate patients 
at baseline for these variables and rely on self reporting.  The other important consideration is 
whether the increased incident cardiovascular risk is causally related to sleep directly or 
whether abnormal sleep patterns may contribute to adverse health behaviors that increase 
cardiovascular risk thereby contributing to the increase in cardiovascular events.   
Several studies have evaluated the mismatch between self-reported sleep and more 
objective measures. An analysis of 669 participants in the CARDIA Sleep Study suggests a 
moderate correlation between self-reported and objectively measured sleep duration with 
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evidence of systematic errors in the mean and calibration.(98) Another study of 2,086 
Hispanic Americans suggests a moderate correlation between self-reported sleep and 
actigraphy results.(99) A smaller study compared self-reported sleep and actigraphy in 56 
participants reported a poor agreement between sleep duration and quality as assessed by a 
questionnaire and objectively measure sleep.(100) In addition, a different analysis of 63 
patients overweight and obese individuals who underwent actigraphy also reported a weak 
correlation between usual sleep time and actigraph estimates.(101) With respect to 
cardiovascular risk, studies suggest that self-reported sleep duration are different from 
objectively assess sleep duration.(102,103) While the exact reasons for discrepancies between 
subjective and objective measures is not clear, it appears that self-reported sleep is only at 
best moderately correlated with objective measures of sleep and perhaps multiple measure of 
sleep duration should be recommended for future studies. 
In the current analysis, the study by Kripke et al(53) represented more than a third of 
the entire cohort and this large study has implications to the interpretation of the results. This 
cohort was a diverse group of adults who were friends or relatives of American of Cancer 
Society volunteers who were aged between 30 and 102 years.  The mean age in this study 
was 57 years and 43% of participants were female which were both slightly lower than the 
average of 60 years of age and 52% female in all the included studies. In addition, the study 
took place in the 1980s which may affect the applicability of its findings to the current 
population. Collectively, these findings may limit the generalizability of the current study. 
 Our study has a number of limitations. While we used adjusted estimates where 
available, there is likely to be residual or unmeasured confounding and bias. For example, an 
underlying physical or mental health condition may be the driver behind extreme sleep 
patterns. A key limitation was that sleep duration was assessed by self-reported 
questionnaires. It is unclear if this is truly reflective of actual sleep patterns as there are 
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studies which clearly show that with respect to cardiovascular risk, self-reported sleep 
duration and objectively assessed sleep duration are significantly different. (102,103) Another 
limitation was the absence of individual patient level data, so we could not make assumptions 
about the cardiovascular risk factor profiles of patients based on their sleep duration or 
quality.  Some studies did report baseline risk factors for patients, but every study reported 
different risk factors, and the combinations of the risk factors profiles reported was too 
heterogeneous to make general assumptions. While we demonstrated an association between 
sleep quality, duration and outcomes, these relationships cannot infer causality and it is 
unclear whether sleep duration or quality is a marker of prevalent cardiovascular risk, an 
adverse cardiovascular risk factor profile or adverse health behaviors that contribute to the 
adverse outcomes reported.  
Conclusion 
 In conclusion, we found a significant association between deviations in sleep duration 
and both mortality and adverse cardiovascular outcomes. National guidelines should consider 
advocating this as the recommended sleep duration.  We also found evidence that sleep 
duration above the recommended level of 7-8 hours was associated with a moderate degree of 
harm compared to sleeping less than the suggested duration.  Furthermore, the greater the 
divergence from the recommended durations of sleep, the greater the association for 
cardiovascular harm and mortality. Our study suggests that abnormal sleep is a marker of 
elevated cardiovascular risk – and greater consideration should be given in exploring during 
patient consultations both the duration and quality of sleep. 
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Table 1: Study design and demographics table 
Study ID Design; Country; Year No. of 
participants 
Mean age % Male Participant inclusion criteria 
Akersted 2017 
(21) 
Prospective cohort study; Sweden; 1997-
2010. 
43,868 51 36 Participants were >18 years in the Swedish National March study. 
Amagai 2010 (22) Prospective cohort study; Japan; April 
1992-July 1995. 
11,367 55 39 Participants were adults of varying ages in 12 rural areas of Japan from the Jichi Medical School Cohort Study. 
Aurora 2016 (23) Prospective cohort study; USA; 1995-2011. 5,784 64 46 Participants were age 40 years and not treated for sleep-disordered breathing in the Sleep Heart Health 
Study. 
Ayas 2003 (24) Prospective cohort study; USA; 1986-1996. 71,617 Unclear 0 Participants were US female health professionals aged 45-65 years who were enrolled in the Nurses’ Health 
Study. 
Bellavia 2014 
(25) 
Prospective cohort study; Sweden; 1998-
2012. 
70,973 Unclear 53 Participants were Swedish males and aged 45-79 years females aged 39-76 years from the population based 
Cohort of Swedish Men and the Swedish Mammography Cohort. 
Burazeri 2003 
(26) 
Prospective cohort study; Israel; 1985 with 
up to 11 years follow up. 
1,842 Unclear 46 Participants were age >50 years in West Jerusalem in the Kiryat Yovel Community Health Study. 
Cai 2015 (27) Prospective cohort study; China; 1996-
2010. 
113,138 54 41 Participants were Chinese men and women in Shanghai, China in the Shanghai Women's Health Study and 
the Shanghai Men's Health Study. 
Canivet 2014 (28) Prospective cohort study; Sweden; 1991-
2005. 
13,617 Unclear 43 Participants were all people between the ages of 45 and 65 residing in Malmo, Sweden from the Malmo Diet 
and Cancer Study 1991. 
Castro-Costa 
2011 (29) 
Prospective cohort study; Brazil; 1997-
2005. 
1,512 Median 
69 
38 Participants were all residents of Bambui city, Brazil aged 60 years and over on 1st January 1997 and part of 
the Bambui Cohort Study. 
Chandola 2010 
(30) 
Prospective cohort study; England; 1985-
1988 
10,308 Unclear 67 Participants were adults aged 35-55 years from 20 London based civil service departments in the Whitehall II 
Cohort. 
Chen 2008 (31) Prospective cohort study; USA; 1994-1998. 93,175 Unclear 0 Participants were postmenopausal women aged 50-79 years from all over the United States in the Women’s 
Health Initiative Observational study cohort. 
Chen 2013 (32) Prospective cohort study; Taiwan; 1999-
2002. 
4,064 73.8 56 Participants were residents of the Shih-Pai area of Taipei, Taiwan who were over 65 years of age and part of 
the Shih-Pai Sleep Study. 
Chien 2010 (33) Prospective cohort study; Taiwan; 1990-
1991. 
3,430 54.8 50 Participants were adults aged over 35 in the Chin-Shan Community Cardiovascular Cohort study and of 
Chinese ethnicity living in Chin-Shan township, Taiwan. 
Cohen-Mansfeld 
2012 (34) 
Prospective cohort study; Israel; 1989-
1992. 
1,166 83 55 Participants were older Jewish adults age >75 years in the Cross-Sectional and Longitudinal Aging Study. 
Ensrud 2012 (35) Prospective cohort study; USA; 2003-2005. 2,505 76 100 Participants were non-frail males aged 65 or over, recruited via the prospective Osteoporotic Fractures in 
Men study. 
Gangwisch 2008 
(36) 
Prospective cohort study; USA; 1982-1992. 9,789 Unclear 37 Participants were men and women age 25-74 years in the NHANES I epidemiologic follow-up study. 
Garde 2013 (37) Prospective cohort study; Denmark; 1970-
2001. 
5,249 49 100 Participants were in the Copenhagen Male Study who were all men aged 40-59 at 14 companies were 
invited. 
Gianfagna 2016 
(38) 
Prospective cohort study; Italy; 1986-
2008. 
2,277 51 100 Participants were men aged 35-74 years and CVD free in the MONICA-Brianza and PAMELA population based 
cohorts. 
Goto 2013 (39) Prospective cohort study; Japan; 1987-
1999. 
724 Unclear 65 Participants were age 65 or over in Okinawa Japan. 
Hale 2013 (40) Prospective cohort study; USA; 1993-2009. 3,942 62 0 Participants were in the Women’s Health Initiative clinical trial and observational study who were 
postmenopausal women aged 50-79 and did not have history of coronary heart disease. 
Hall 2015 (41) Prospective cohort study: USA; 1997 start 
follow up of 9 years. 
3,013 73.6 48.6 Participants were adults in the Health, Aging and Body Composition Study.  
Hamazaki 2011 
(42) 
Prospective cohort study; Japan; 1994-
2008. 
2,282 44 100 Participants were men aged 35-54 years old at a light metal factory (Japan) who did not have previous 
cardiovascular event or missing information at baseline survey. 
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Helbig 2015 (43) Prospective cohort study; Germany; 1984-
2001. 
17,604 48 50 Participants were age 25-74 years in the Monitoring Trends and Determinants in Cardiovascular 
Disease/Cooperative Health Research in the Region of Augsburg study.  
Heslop 2002 (44) Prospective cohort study; Scotland; 1970-
1995. 
3,030 Unclear 85 Participants were working Scottish men and women recruited between 1970 and 1973.  
Hoevenaar-Blom 
2011 (12) 
Prospective cohort study; Netherlands; 
1993-2012. 
20,432 42 45 Participants were age 20-65 years in the MORGEN study. 
Huang 2013 (45) Prospective cohort study; Taiwan; 1999-
2010. 
1901 Unclear 51 Participants were aged ≥65 years in the Elderly Nutrition and Health Survey in Taiwan. 
Hublin 2007 (46) Prospective cohort study; Finland; 1975-
2003. 
21,268 41 48 Participants were in Finnish Twin Cohort who were all Finnish twin pairs of same sex born before 1958 with 
both co-twins alive in 1975. 
Ikehara 2009 (47) Prospective cohort study; Japan; 1988-
2003. 
98,634 Unclear 42 Participants were in the Japan Collaborative Cohort Study for Evaluation of Cancer Risk where were aged 40-
79 years and living in Japan. 
Jung 2013 (48) Prospective cohort study; USA; 1984-2001. 2,001 74 44 Participants were in the community-dwelling adults age 60-96 years in The Rancho Bernardo Study. 
Kakizaki 2013 
(49) 
Prospective cohort study; Japan; 1994-
2008. 
49,256 60 48 Participants were aged 40-79 years in the Ohsaki Cohort Study. 
Kawachi 2016 
(50) 
Prospective cohort study; Japan; 1992-
2008. 
27,896 54 54 Participants were men and women aged 35 years or older in the Takayama Cohort Study. 
Kim 2013 (51) Prospective cohort study; USA; 1993-2007. 135,685 Unclear 46 Participants were age 45-75 years in the Multiethnic Cohort  Study from Hawaii and Los Angeles. 
Kojima 2000 (52) Prospective cohort study; Japan; 1982-
1996. 
5,322 47 46 Participants were aged 20-76 years from Shirakawa town, Japan. 
Kripke 2002 (53) Prospective cohort study; USA; 1982-1988. 1,116,936 57 43 Participants were age 30-102 years in the Cancer Prevention Study II mainly friends/relatives of American 
Cancer Society volunteers. 
Lan 2007 (54) Prospective cohort study; Taiwan; 1993-
2003. 
3,079 71 55 Participants were ≥64 years or greater in the Survey of Health and Living Status of the Elderly in Taiwan. 
Lee 2014 (55) Prospective cohort study; Hong Kong; 
2001-2010. 
3,427 74 51 Participants were men and women in Hong Kong age ≥65 years. 
Lee 2017 (56) Prospective cohort study; Taiwan; 2006-
2010. 
937 65 55 Participants were Taiwanese aged 53 years or older in the Social Environment and Biomarkers of Aging 
Study. 
Leng 2015 (9) Prospective cohort study; United 
Kingdom; 1998-2009. 
9,692 62 46 Participants were adults age 42-81 years in the European Prospective Investigation into Cancer-Norfolk 
cohort. 
Li 2013 (57) Prospective cohort study; Japan; 1983-
1990. 
12,489 Unclear 38 Participants were residents age 20-79 years in the Minami Saku area of Japan who were a part of the 
SAKUCESS project. 
Liu 2014 (58) Prospective cohort study; USA; 1971-2007. 3,381 45 48 Participants were age >30 and were free from coronary heart disease in the Framingham Offspring Study. 
Magee 2011 (59) Prospective cohort study; Australia; 2006-
2009. 
218,155 63 47 Participants were Australian adults aged ≥45 years, residing in the state of New South Wales and part of the 
45 and Up study. 
Magee 2013 (60) Prospective cohort study; Australia; 2006-
2009. 
227,815 Unclear 46.3 Participants were Australian adults aged ≥45 years, residing in the state of New South Wales and part of the 
45 and Up study. 
Mallon 2002 (61) Prospective cohort study; Sweden; 1983-
1995. 
1,870 56 48 Participants were a random adults aged 45-65 years in the population register of the County of Dalarna in 
Sweden. 
Martin 2011 (62) Prospective cohort study; USA; Unclear. 245 81 62 Participants were adults aged ≥65 years admitted to post-acute rehabilitation sites in the Los Angeles area in 
USA. 
Meisinger 2007 
(63) 
Prospective cohort study; Germany; 1984-
1995. 
6,896 58 50.9 Participants were German adults aged 45-74 years which were part of the MONICA Augsburg project. 
Mesas  2010 (64) Prospective cohort study; Spain; 2001-
2008. 
3,820 71.8 44 Participants were noninstitutionalized adults aged ≥60 year living in Spain. 
Pan 2014 (65) Prospective cohort study; Singapore; 
1993-1998. 
63,257 57 44 Participants were Chinese adults in Singapore aged 45-74, recruited from Hokkiens and Cantonese dialect 
groups residing in government housing estates. 
Patel 2004 (66) Prospective cohort study; USA; 1986-2000. 82,969 53 0 Participants were women aged 30-55 years and residing in 11 US states that were part of the Nurses’ Health 
Study. 
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Pollak 1990 (67) Prospective cohort study; USA; 1984-1985. 1,855 75 Unclear Participants were elderly residents of an urban community age 65-98 years. 
Qiu 2011 (68) Prospective cohort study; China; 2005-
2008. 
12,671 86 57 Participants were elderly Chinese adults from 22 provinces in China in the Chinese Longitudinal Healthy 
Longevity Survey. 
Qureshi 1997 
(69) 
Prospective cohort study; USA; 1982-1992. 7,844 Unclear 36 Participants were US civilian noninstitutionalized adults aged >31 years and in the NHANES I Epidemiologic 
Follow-up Study (NHEFS). 
Rhee 2012 (70) Prospective cohort study; Korea; 1992-
2008. 
14,533 51 100 Participants were male subjects age 40-59 years in the Seoul Male Cohort Study. 
Rod 2014 (71) Prospective cohort study; UK; 1985-2010. 9,098 45 67 Participants were in the Whitehall II Cohort Study who were London-based office staff aged 35 to 55 years 
working in 20 civil service departments in 1985. 
Ruigomez 1995 
(72) 
Prospective cohort study; Spain; 1986-
1991. 
1219 Unclear 39 Participants were elderly population in the 1986 Health Interview Survey of Barcelona. 
Ruiter Petrov 
2014 (73) 
Prospective cohort study; USA; 2003-2010. 5,666  61 44 Participants were aged ≥45 years in the Reasons for Geographic And Racial Differences in Stroke study. 
Sands-Lincoln 
2013 (74) 
Prospective cohort study; USA; 1993-2009. 86,329 63 0 Participants were in the Women’s Health Initiative clinical trial  and observational study who were 
postmenopausal women aged 50-79 and did not have history of coronary heart disease. 
Shankar 2008 
(75) 
Prospective cohort study; Singapore; 
1993-2006. 
58,044 56 44 Participants were Chinese adults age 45-75 years in the Singapore Chinese Health Study.  
Song 2016 (76) Prospective cohort study; China; 2006-
2010. 
95,203 51 79 Participants were age 18-98 years in the Kailuan study. 
Stone 2009 (77) Prospective cohort study; USA; Unclear. 6,107 80 50 Participants were community-dwelling older adults participating in the Study of Osteoporotic Fractures and 
the Outcomes of Sleep Disorders in Older Men Study. 
Strand 2016 (78) Prospective cohort study; Taiwan; 1998-
2011. 
392,164 40 49 Participants were Taiwanese adults age 20 years who participants in health check-up program run by MJ 
Health Management Institution. 
Suzuki 2009 (11) Prospective cohort study; Japan; 1999-
2006. 
12,601 74 51 Participants are elderly residence age 65-85 years in the Shizuoka Study. 
Tamakoshi 2004 
(79) 
Prospective cohort study; Japan; 1988-
1999. 
104,010 58 42 Participants were age 40-79 years in the Japan Collaborative Cohort Study on Evaluation of Cancer Risk study. 
Tsubono 1993 
(80) 
Prospective cohort study; Japan; 1988-
1992. 
4,318 Unclear 40 Participants were ≥40 years in Japan who participated in the annual health examination program 
implemented by the Town Council. 
Tu 2012 (81)  Prospective cohort study; China; 1997-
2006. 
68,832 60 0 Participants were women age 40-70 years in the Shanghai Women’s Health Study. 
Twig 2016 (82) Prospective cohort study; Israel; Unclear. 23,690 30 100 Participants were men older than 25 years in the Israeli Defense Forces who were in the MELANY cohort 
study. 
Von Ruesten 
2012 (83) 
Prospective cohort study; Germany; 1994-
2007. 
23,620 49 39 Participants were in the European Prospective Investigation into Cancer and Nutrition (EPIC) study in 
Potsdam. 
Wang 2016 (84) Prospective cohort study; China; 2006-
2010. 
95,903 51 80 Participants were age 18-98 years in the Kailuan study. 
Werle 2011 (85) Prospective cohort study; Brazil; 1994-
2009. 
187 84 36 Participants were >80 years in the city of Veranopolis, Brazil. 
Westerlund 2013 
(8) 
Prospective cohort study; Sweden; 1997-
2010. 
41,192 Unclear 35 Participants were ≥18 years in the Swedish National March Cohort Study. 
Wingard 1983 
(86) 
Prospective cohort study; USA; 1965-1974. 6928 Unclear 47 Participants were 30-69 years of age in 1965 in California, USA. 
Xiao 2014 (87) Prospective cohort study; USA; 1995-2011 239,896 63 56 Participants were 51-72 years in the NIH AARP Diet and Health Study. 
Yeo 2013 (88) Prospective cohort study; Korea; 1993-
2010. 
13,164 55 41 Participants were ≥20 years in the Korean Multi-center Cancer Cohort study. 
Zawisza 2015 
(89) 
Prospective cohort study; Poland; 1986-
2008. 
2,449 72 35 Participants were ≥65 years from Krakow city centre in Poland. 
Zuubier 2015 Prospective cohort study; Netherlands; 1,734 62 47 Participants were ≥45 years in the Rotterdam Study. 
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(90) 2004-2013. 
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 Table 2: Study cohort, follow up and results for studies with authors A-L. 
Study ID Follow up duration Outcomes and crude rate of 
outcomes 
Results 
Akersted 2017 (21) 13 years. All-cause mortality: 
3,548/39,191. 
Sleep duration and mortality: ≤5h: aHR 1.12 (0.99-1.27), 6h: aHR 0.98 (0.88-1.09), 7h: aHR 1.00, ≥8h: aHR 1.10 (1.00-1.20). 
Amagai 2010 (22) 10.7 years. CVD events: 481/11,367. MI: 
80/11,367. Stroke: 411/11,367.  
Sleep duration and CVD in males: <5.9h: aHR 2.14 (1.11-4.13), 6.0-6.9h: aHR 1.04 (0.61-1.76), 7.0-7.9h: aHR 1.00, 8.0-8.9h: aHR 0.98 (0.69-1.40), ≥9.0h: aHR 1.33 (0.93-1.92). 
Sleep duration and CVD in females: <5.9h: aHR 1.46 (0.70-3.04), 6.0-6.9h: aHR 0.64 (0.38-1.10), 7.0-7.9h: aHR 1.00, 8.0-8.9h: aHR 0.85 (0.60-1.20), ≥9.0h: aHR 1.28 (0.88-1.87). 
Sleep duration and MI in men: <5.9h: aHR 1.78 (0.50-6.28), 6.0-6.9h: aHR 0.77 (0.25-2.33), 7.0-7.9h: aHR 1.00, 8.0-8.9h: aHR 0.69 (0.34-1.41), ≥9.0h: aHR 0.99 (0.47-2.06). 
Sleep duration and MI in women: <5.9h: aHR 4.93 (1.31-18.61), 6.0-6.9h: aHR 0.59 (0.13-2.73), 7.0-7.9h: aHR 1.00, 8.0-8.9h: aHR 0.59 (0.21-1.66), ≥9.0h: aHR 0.84 (0.27-2.62). 
Sleep duration and stroke in men: <5.9h: aHR 2.00 (0.93-4.31), 6.0-6.9h: aHR 1.13 (0.63-2.03), 7.0-7.9h: aHR 1.00, 8.0-8.9h: aHR 1.03 (0.69-1.53), ≥9.0h: aHR 1.39 (0.92-2.10). 
Sleep duration and stroke in women: <5.9h: aHR 0.97 (0.39-2.41), 6.0-6.9h: aHR 0.68 (0.39-1.18), 7.0-7.9h: aHR 1.00, 8.0-8.9h: aHR 0.86 (0.60-1.23), ≥9.0h: aHR 1.29 (0.86-1.91).  
Aurora 2016 (23) 10.8 years. All-cause mortality: 1,509/5,784. Sleep duration and mortality: <7h: aHR 0.98 (0.87-1.10), 7-8h: aHR 1.00, ≥9h: aHR 1.25 (1.05-1.47).  
Ayas 2003 (24) 10 years. CHD: 934/71,617. Sleep duration and CHD: ≤5h: aOR 1.39 (1.05-1.84), 6h: aOR 1.18 (0.98-1.43), 7h: aOR 1.10 (0.92-1.31), 8h: aOR 1.00, >9h: aOR 1.37 (1.02-1.85). 
Bellavia 2014 (25) 15 years. All-cause mortality 
13,450/70,973. CVD mortality: 
3,981/70,973.  
Sleep duration and all-cause mortality: <6h: aHR 1.25 (1.13-1.37), 6-6.5h: aHR 1.10 (1.04-1.17), 6.6-7.4h: aHR 1.00 (reference), 7.5-8h: aHR 1.03 (0.98-1.08), >8h: aHR 1.14 (1.05-1.24).  
Sleep duration and CVD mortality: <6h: aHR 1.44 (1.20-1.73), 6-6.5h: aHR 1.23 (1.09-1.38), 6.6-7.4h: aHR 1.00, 7.5-8h: aHR 1.02 (0.92-1.12), >8h: aHR 1.11 (0.95-1.31). 
Burazeri 2003 (26) 10 years. All-cause mortality: 403/1,842. Total sleep duration and all-cause mortality in men: <6h: aHR 1.00, 6-8h: aHR 1.41 (0.83-2.39), >8h: aHR 2.13 (1.23-3.71).  
Total sleep duration and all-cause mortality in women: <6h: aHR 1.00, 6-8h: aHR 0.63 (0.42-0.97), >8h: aHR 0.80 (0.51-1.24). 
Total sleep duration and CVD mortality in men: <6h: aHR 1.00, 6-8h: aHR 1.54 (0.75-3.15), >8h: aHR 2.02 (1.01-4.03). 
Total sleep duration and CVD mortality in women: <6h: aHR 1.00, 6-8h: aHR 0.69 (0.37-1.29), >8h: aHR 0.79 (0.42-1.48). 
Cai 2015 (27) Median 6-7 years. All-cause mortality: 
4,277/113,138. 
Sleep duration and all-cause mortality: 4-5h: aHR 1.11 (1.00-1.23), 6h: aHR 1.06 (0.97-1.16), 7h: aHR 1.00, 8h: aHR 1.15 (1.05-1.26), 9h: aHR 1.34 (1.17-1.54), ≥10h: 1.81 (1.59-2.06).  
Sleep duration and all-cause mortality in men: 4-5h: aHR 1.06 (0.90-1.25), 6h: aHR 1.07 (0.94-1.23), 7h: aHR 1.00, 8h: aHR 1.13 (1.00-1.28), 9h: aHR 1.34 (1.10-1.62), ≥10h: aHR 1.55 (1.29-1.86). 
Sleep duration and all-cause mortality in women: 4-5h: aHR 1.15 (1.01-1.32), 6h: aHR 1.06 (0.94-1.20), 7h: aHR 1.00, 8h: aHR 1.17 (1.04-1.32), 9h: aHR 1.36 (1.13-1.64), ≥10h: aHR 2.11 (1.77-2.52).  
Sleep duration and cardiovascular mortality: 4-5h: aHR 1.05 (0.87-1.26), 6h:aHR 1.10 (0.94-1.29), 7h: aHR 1.00, 8h: aHR 1.22 (1.05-1.43), 9h: aHR 1.47 (1.17-1.85), ≥10h: aHR 2.04 (1.65-2.53). 
Sleep duration and cardiovascular mortality in men: 4-5h: aHR 1.09 (0.82-1.46), 6h: aHR 1.06 (0.83-1.34), 7h: aHR 1.00, 8h: aHR 1.25 (1.00-1.56), 9h: aHR 1.68 (1.23-2.30), ≥10h: aHR 1.58 (1.14-2.18). 
Sleep duration and cardiovascular mortality in women: 4-5h: aHR 1.02 (0.80-1.30), 6h: aHR 1.12 (0.91-1.39), 7h: aHR 1.00, 8h: aHR 1.20 (0.96-1.50), 9h: aHR 1.28 (0.91-1.82), ≥10h: aHR 2.64 (1.99-3.52).  
Sleep duration and stroke mortality: 4-5h: aHR 0.91 (0.70-1.18), 6h: aHR 0.99 (0.79-1.23), 7h: aHR 1.00, 8h: aHR 1.28 (1.04-1.58), 9h: aHR 1.31 (0.94-1.82), ≥10h: aHR 2.35 (1.78-3.09). 
Sleep duration and stroke mortality in men: 4-5h: aHR 0.93 (0.62-1.40), 6h: aHR 0.78 (0.55-1.10), 7h: aHR 1.00, 8h: 1.20 (0.89-1.62), 9h: aHR 1.62 (1.06-2.48), ≥10h: aHR 1.73 (1.14-2.64). 
Sleep duration and stroke mortality in women: 4-5h: aHR 0.92 (0.65-1.29), 6h: aHR 1.14 (0.85-1.52), 7h: aHR 1.00, 8h: aHR 1.36 (1.01-1.82), 9h: aHR 0.98 (0.58-1.66), ≥10h: aHR 3.09 (2.14-4.47). 
Canivet 2014 (28) 14 years. Unclear. Sleep duration and CV events in men: ≤6h: aHR 1.1 (0.96-1.3), 7-8h: aHR 1.0, ≥9h:aHR 1.3 (1.01-1.7). 
Sleep duration and CV events in women: ≤6h: aHR 1.3 (1.1-1.5), 7-8h: aHR 1.0, ≥9h: aHR 1.5 (1.1-2.1). 
Castro-Costa 2011 
(29) 
Unclear. All-cause mortality: 440/1,512. Night-time sleep duration and all-cause mortality: <6h: aHR 1.09 (0.78-1.53), 6-7h: aHR 0.84 (0.60-1.17), 7-8h: aHR 1.00 (reference), 8-9h: aHR 1.31 (0.97-1.78), ≥9h: aHR 1.53 (1.12-2.09). 
Chandola 2010 (30) 15 years. CHD mortality, MI, angina: 
1,205/8,998. 
Sleep duration and CHD mortality, MI and angina: <5h: aRR 1.05 (0.92-1.20), 6h: aRR 0.98 (0.83-1.16), 7h: aRR 1.00, >8h: aRR 0.99 (0.77-1.27). 
Poor sleep quality (more than usual restless, disturbed nights) and CHD mortality, MI and angina: aRR 1.36 (1.10-1.68). 
Chen 2008 (31) 7.5 years. Ischaemic stroke: 1,166/93,175. Sleep duration and ischemic stroke: <6h: aHR 1.14 (0.97-1.33), 7h: aHR 1.00, 8h: aHR 1.24 (1.04-1.47), >9h: aHR 1.70 (1.32-2.21). 
Chen 2013 (32) 9 years. All-cause mortality: 1,004/4,064. 
CVD mortality: 259/4,064. 
Sleep duration and all-cause mortality: <4h: aHR 1.00 (0.75-1.33), 5h: aHR 0.92 (0.74-1.15), 6h: aHR 0.88 (0.73-1.06), 7h: aHR 1.00, 8h: aHR 1.26 (1.04-1.53), >9h: aHR 1.66 (1.28-2.17). 
Sleep duration and CVD mortality: <4h: aHR 1.05 (0.61-1.79), 5h:aHR 0.95 (0.62-1.48), 6h:aHR 0.79 (0.54-1.16), 7h: aHR 1.00, 8h: aHR 1.36 (0.92-2.01), >9h: aHR 2.36 (1.46-3.80). 
Poor sleep quality (subjective) and all-cause mortality: aHR 0.81 (0.47-1.38).  
Poor sleep quality (subjective) and CVD mortality: aHR 0.60 (0.19-1.93).  
Chien 2010 (33) Median 15.9 years. All-cause mortality: 901/3,430. 
CVD events: 420/3,430.  
Sleep duration and all-cause mortality: <5h: aRR 1.15 (0.9-1.46), 6h: aRR 0.97 (0.79-1.21), 7h: aRR 1, 8h: aRR 1.04 (0.86-1.27), ≥9h: aRR 1.34 (1.08-1.67). 
Sleep duration and CVD event: <5h: aRR 0.94 (0.65-1.35), 6h: aRR 0.91 (0.67-1.24), 7h: aRR 1, 8h: aRR 1.05 (0.80-1.39), >9h: aRR 1.12 (0.81-1.55). 
Cohen-Mansfeld 
2012 (34) 
20 years. All-cause mortality: 1,108/1,166. Sleep duration and mortality: <7h: aHR 0.98 (0.84-1.13), 7-9h: 1.00, >9h: aHR 1.32 (1.09-1.58). 
Ensrud 2012 (35) 3.4 years. All-cause mortality: 180/2,505. Poor sleep quality (PSQI score >5) and all-cause mortality: >5 81/1,018 vs ≤5 99/1,487, aOR 1.02 (0.73-1.42). 
Sleep duration and all-cause mortality: ≤5h: 21/269 vs 159/2236, aOR 1.08 (0.65-1.80). 
Gangwisch 2008 (36) Up to 10 years. All-cause mortality: 1,877/9,789. Sleep duration and all-cause mortality: ≤5h: aHR 1.17 (0.99-1.39), 6h: aHR 0.95 (0.81-1.11), 7h: aHR 1.00, 8h: aHR 1.23 (1.08-1.39), ≥9h: aHR 1.34 (1.15-1.56).  
Garde 2013 (37) 30 years. All-cause mortality: 2,643/5,249. 
Ischaemic heart disease 
mortality: 587/5,249.  
Sleep duration on all-cause mortality in men: <6h: aHR 1.06 (0.90-1.25). 6-7h: aHR 1.00. ≥8h: aHR 0.99 (0.84-1.09). 
Sleep duration and ischemic heart disease mortality in men: <6h: aHR 1.46 (1.07-2.00). 6-7h: aHR 1.00. ≥8h: aHR 1.20 (0.97-1.49). 
Gianfagna 2016 (38) Median 17 years. CVD event: 293/2,277. CHD 
event: 214/2,277. 
Sleep duration and CVD event: ≤6h: aHR 1.14 (0.84-1.53), 7-8h: aHR 1.00, ≥9h: aHR 1.55 (1.08-2.21). 
Sleep duration and CHD event: ≤6h: aHR 1.14 (0.80-1.61), 7-8h: aHR 1.00, ≥9h: aHR 1.32 (0.85-2.07). 
Sleep disturbance on CVD event vs none/some: moderate aHR 1.14 (0.74-1.77), severe aHR 1.80 (1.07-3.03). 
Sleep disturbance on CHD event vs none/some: moderate aHR 1.35 (0.83-2.21), severe aHR  1.83 (0.98-3.41). 
Goto 2013 (39) 12 years. All-cause mortality: 305/724. Sleep duration and all-cause mortality in men: aHR <6h: aHR 1.29 (0.50-3.34), 6-7h: aHR 1.00, >7h: aHR 1.54 (092-2.58). 
Sleep duration and all-cause mortality in women: aHR <6h: aHR 2.62 (1.36-5.07), 6-7h: aHR 1.00, >7 h: aHR 1.40 (0.91-2.15). 
Hale 2013 (40) Up to 16 years. All-cause mortality: 335/3,942. Sleep duration and all-cause mortality: ≤5h: aOR 1.01 (0.68-1.51), 6h: aOR 0.94 (0.71-1.24), 7-8h: aOR 1.00, ≥9h: aOR 1.55 (0.92-2.60). 
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CHD: 132/3,942. Sleep duration and CHD: ≤5h: aOR 1.09 (0.63-1.89), 6h: aOR 0.66 (0.42-1.04), 7-8h: aOR 1.00, ≥9h: aOR 1.88 (0.92-3.83). 
Hall 2015 (41) 9 years. All-cause mortality: 953/3,075. Sleep duration and all-cause mortality: <6h: aHR 1.06 (0.83-1.34), 6h: aHR 1.00 (0.82-1.22), 7h: aHR 1.00, 8h: aHR 1.10 (0.91-1.33), >8h: aHR 1.23 (0.93-1.63). 
Hamazaki 2011 (42) 14 years. CVD events: 64/2,282. Stroke: 
30/2,282. Coronary events: 
27/2,282. 
Sleep duration and CVD events: <6h: aHR 3.49 (1.30-9.40), 6-6.9h: aHR 1.11 (0.55-2.25), 7-7.9h: aHR 1.00, ≥8h: aHR 1.71 (0.90-3.24). 
Sleep duration and stroke: <6h: aHR 1.84 (0.23-14.90), 6-6.9h: aHR 0.96 (0.30-3.10), 7-7.9h: aHR 1.00, ≥8h: aHR 2.25 (0.91-5.57). 
Sleep duration and coronary events: <6h: aHR 4.95 (1.31-18.73), 6-6.9h: aHR 1.12 (0.40-3.13), 7-7.9h: aHR 1.00 (reference), ≥8h: aHR 1.78 (0.67-4.76). 
Helbig 2015 (43) 14 years. Stroke: 917/17,604. Sleep duration and strokes in men: ≤5h: aHR 1.36 (0.95-1.94), 6h: aHR 0.92 (0.70-1.22), 7-8h: aHR 1.00, 9h: aHR 1.05 (0.78-1.43), ≥10h: aHR 1.38 (0.98-1.94). 
Sleep duration and strokes in women: ≤5h: aHR 0.68 (0.40-1.18), 6h: aHR 1.25 (0.91-1.70), 7-8h: aHR 1.00, 9h: aHR 1.09 (0.76-1.57), ≥10h: aHR 0.91 (0.55-1.51). 
Poor sleep quality (difficulty staying asleep) and stroke in men: aHR 1.06 (0.87-1.30). 
Poor sleep quality (difficulty staying asleep) and stroke in women: aHR 0.87 (0.68-1.10). 
Heslop 2002 (44) 25 years. All-cause mortality: 1,062/7,028. 
CVD mortality: 557/7,028.  
Sleep duration and all-cause mortality in men: <7h: aHR 1.15 (0.93-1.42), 7-8h: aHR 1.00, >8h: aHR 0.91 (0.57-1.46). 
Sleep duration and all-cause mortality in women: <7h: aHR 1.73 (0.99-3.03), 7-8h: 1.00, >8h: aHR 0.58 (0.08-4.22). 
Sleep duration and CVD mortality in men: <7h: aHR 1.19 (0.90-1.58), 7-8h: aHR 1, >8h: aHR 0.63 (0.30-1.34). 
Sleep duration and CVD mortality in women:  <7h: aHR 2.30 (0.94-5.60), 7-8h: aHR 1, >8h: aHR 1.53 (0.20-11.8). 
Hoevenaar-Blom 
2011 (12) 
11.9 years. CVD events: 1,486/20,432. CHD: 
1,148/20,432.  
Sleep duration on incident CVD: ≤6h: aHR 1.11 (0.97-1.27), 7h: aHR 1.00, 8h: aHR 0.95 (0.84-1.08), ≥9h: aHR 0.96 (0.77-1.18). 
Sleep duration and incident CHD: ≤6h: aHR 1.19 (1.00-1.40), 7h: aHR 1.00, 8h: aHR 0.85 (0.73-1.00), ≥9h: aHR 0.78 (0.58-1.04). 
Poor sleep quality and incident CVD: aHR 1.04 (0.87-1.26). 
Poor sleep quality and incident CHD: aHR 1.19 (0.96-1.50). 
Huang 2013 (45) 10 years. All-cause mortality: 182/1,865. Poor sleep quality (good vs poor) and all-cause mortality in men: aHR 0.60 (0.42-0.87). 
Poor sleep quality (good vs poor) and all-cause mortality in women: aHR 0.99 (0.68-1.45). 
Hublin 2007 (46) 22 years. All-cause mortality: 
3,700/21,268.  
Sleep duration and all-cause mortality in men: <7h: aHR 1.26 (1.11-1.43), 7-8h: aHR 1.00, >8h: aHR 1.24 (1.09-1.41). 
Sleep duration and all-cause mortality in women: <7h: aHR 1.21 (1.05-1.40), 7-8h: aHR 1.00, >8h: aHR 1.17 (1.03-1.34). 
Poor sleep quality and all-cause mortality in men: aHR 1.10 (0.87-1.39).  
Poor sleep quality and all-cause mortality in women: aHR 0.99 (0.77-1.27). 
Ikehara 2009 (47) Median 14.3 years. All-cause mortality 
14,540/98,634. CVD mortality 
4,287/98,634. Stroke mortality: 
1,964/98,634. CHD mortality 
881/98,634. 
Sleep duration and all-cause mortality in men: ≤4h: aHR 1.29 (1.02-1.64), 5h: aHR 1.02 (0.90-1.16), 6h: aHR 1.08 (1.00-1.16), 7h: aHR 1.00, 8h: aHR 1.06 (1.00-1.12), 9h: aHR 1.13 (1.05-1.22), ≥10h: aHR 1.41 (1.29-1.54). 
Sleep duration and all-cause mortality in women: ≤4h: aHR 1.28 (1.03-1.60), 5h: aHR 1.11 (0.98-1.25), 6h: aHR 1.05 (0.97-1.14), 7h: aHR 1.00, 8h: aHR 1.16 (1.08-1.24), 9h: aHR 1.32 (1.20-1.45), ≥10h: aHR 1.56 (1.40-1.75). 
Sleep duration and CVD mortality in men: ≤4h: aHR 1.11 (0.67-1.83), 5h: aHR 0.99 (0.77-1.27), 6h: aHR 1.01 (0.87-1.18), 7h: aHR 1.00, 8h: aHR 1.11 (1.00-1.24), 9h: aHR 1.14 (0.99-1.32), ≥10h: aHR 1.56 (1.33-1.83). 
Sleep duration and CVD mortality in women: ≤4h: aHR 1.28 (0.88-1.86), 5h: aHR 1.22 (1.00-1.50), 6h: aHR 1.00 (0.86-1.16), 7h: aHR 1.00, 8h: aHR 1.28 (1.14-1.44), 9h: aHR 1.37 (1.17-1.62), ≥10h: aHR 1.54 (1.28-1.86). 
Sleep duration and stroke mortality in men: ≤4h: aHR 1.56 (0.82-2.94), 5h: aHR 0.85 (0.58-1.26), 6h: aHR 0.95 (0.76-1.20), 7h: aHR 1.00, 8h: aHR 1.11 (0.95-1.30), 9h: aHR 1.14 (0.92-1.42), ≥10h: aHR 1.66 (1.31-2.08). 
Sleep duration and stroke mortality in women: ≤4h: aHR 1.07 (0.59-1.91), 5h: aHR 0.99 (0.72-1.37), 6h: aHR 0.93 (0.75-1.16), 7h: aHR 1.00, 8h: aHR 1.24 (1.05-1.47), 9h: aHR 1.29 (1.01-1.64), ≥10h: aHR 1.69 (1.29-2.20). 
Sleep duration and CHD mortality in men: ≤4h: aHR 0.29 (0.04-2.05), 5h: aHR 1.02 (0.62-1.70), 6h: aHR 0.86 (0.63-1.19), 7h: aHR 1.00, 8h: aHR 1.02 (0.82-1.27), 9h: aHR 0.96 (0.70-1.31), ≥10h: aHR 1.12 (0.77-1.63). 
Sleep duration and CHD mortality in women: ≤4h: aHR 2.32 (1.19-4.50), 5h: aHR 1.64 (1.07-2.53), 6h: aHR 1.23 (0.88-1.72), 7h: aHR 1.00, 8h: aHR 1.24 (0.94-1.64), 9h: aHR 1.52 (1.05-2.19), ≥10h: aHR 1.04 (0.63-1.72). 
Jung 2013 (48) Up to 19 years. All-cause mortality: 1,224/2,001. Night-time sleep duration and all-cause mortality in men: <6h: aHR 0.98 (0.673-1.43), 6.0-6.9h: aHR 1.12 (0.85-1.48) 7.0-7.9h: aHR 1.0, 8.0-8.9h: aHR 0.98 (0.79-1.22), ≥9h: aHR 1.09 (0.82-1.45). 
Night-time sleep duration and all-cause mortality in women: <6h: aHR 1.11 (0.77-1.60), 6.0-6.9h: aHR 1.17 (0.85-1.61) 7.0-7.9h: aHR 1.0, 8.0-8.9h: aHR 1.19 (0.90-1.57), ≥9h: aHR 1.51 (1.05-2.18). 
Kakizaki 2013 (49) 13 years. All-cause mortality 8,447/49,256. 
CVD mortality 2,549/49,256. 
Stroke mortality 1,165/49,256. 
IHD mortality 561/49,256.  
Sleep duration and all-cause mortality: ≤6h: aHR 1.01 (0.93-1.09), 7h: aHR 1.00, 8h: aHR 1.07 (1.01-1.14), 9h: aHR 1.14 (1.06-1.24), ≥10h: aHR 1.37 (1.27-1.47). 
Sleep duration on CVD mortality: ≤6h: aHR 1.10 (0.96-1.28), 7h: aHR 1.00, 8h: aHR 1.21 (1.08-1.36), 9h: aHR 1.32 (1.15-1.52), ≥10h: aHR 1.49 (1.30-1.71). 
Sleep duration and stroke mortality: ≤6h: aHR 1.05 (0.84-1.30), 7h: aHR 1.00, 8h: aHR 1.17 (0.99-1.39), 9h: aHR 1.30 (1.06-1.60), ≥10h: aHR 1.51 (1.24-1.85). 
Sleep duration and IHD mortality: ≤6h: aHR 1.38 (1.02-1.86), 7h: aHR 1.00, 8h: aHR 1.36 (1.06-1.73), 9h: aHR 1.49 (1.10-2.02), ≥10h: aHR 1.41 (1.04-1.92). 
Kawachi 2016 (50) Up to 16 years. Stroke mortality: 611/27,896  Sleep duration and stroke mortality: ≤6h: aHR 0.77 (0.59-1.01), 7h: aHR 1.00, 8h: aHR 1.13 (0.91-1.40), ≥9h: aHR 1.51 (1.16-1.97). 
Sleep duration and stroke mortality in men: ≤6h: aHR 0.51 (0.34-0.77), 7h: aHR 1.00, 8h: aHR 0.88 (0.66-1.17), ≥9h: aHR 1.23 (0.90-1.69). 
Sleep duration and stroke mortality in women: ≤6h: aHR 1.06 (0.75-1.50), 7h: aHR 1.00, 8h: aHR 1.50 (1.10-2.04), ≥9h: aHR 1.93 (1.38-2.70). 
Kim 2013 (51) 13 years. All-cause mortality: 
19,335/135,685. CVD mortality 
6,610/135,685. Stroke mortality: 
1,259/135,685. MI mortality: 
1,188/135,685. 
Sleep duration and all-cause mortality in men: aHR ≤5h: 1.15 (1.06-1.23), 6h: aHR 1.04 (0.99-1.10), 7h: aHR 1.00, 8h: 1.07 (1.01-1.12), ≥9h: 1.19 (1.12-1.27). 
Sleep duration and all-cause mortality in women: aHR ≤5h: 1.14 (1.06-1.23), 6h: aHR 1.05 (0.99-1.12), 7h: aHR 1.00, 8h: 1.02 (0.96-1.08), ≥9h: 1.22 (1.13-1.31). 
Sleep duration and CVD mortality in men: aHR ≤5h: 1.13 (1.00-1.28), 6h: aHR 1.01 (0.92-1.11), 7h: aHR 1.00, 8h: 1.05 (0.96-1.14), ≥9h: 1.22 (1.09-1.35).  
Sleep duration and CVD mortality in women: aHR ≤5h: 1.20 (1.05-1.36), 6h: aHR 1.06 (0.96-1.18), 7h: aHR 1.00, 8h: 1.08 (0.98-1.20), ≥9h: 1.29 (1.13-1.47). 
Sleep duration and stroke mortality in men: aHR ≤5h: 1.02 (0.74-1.40), 6h: aHR 1.10 (0.88-1.37), 7h: aHR 1.00, 8h: 1.13 (0.91-1.39), ≥9h: 1.35 (1.03-1.75). 
Sleep duration and stroke mortality in women: aHR ≤5h: 1.16 (0.88-1.52), 6h: aHR 0.99 (0.79-1.23), 7h: aHR 1.00, 8h: 1.07 (0.87-1.33), ≥9h: 1.39 (1.06-1.83). 
Sleep duration and MI mortality in men: aHR ≤5h: 1.24 (0.94-1.64), 6h: aHR 0.92 (0.74-1.15), 7h: aHR 1.00, 8h: 0.98 (0.80-1.20), ≥9h: 1.16 (0.89-1.50). 
Sleep duration and MI mortality in women: aHR ≤5h: 1.18 (0.87-1.59), 6h: aHR 1.23 (0.96-1.56), 7h: aHR 1.00, 8h: 1.10 (0.86-1.40), ≥9h: 1.29 (0.95-1.75). 
Kojima 2000 (52) 12 years. All-cause mortality: 256/5,322. Sleep duration and all-cause mortality in men: <7h: aRR 1.93 (1.12-3.35), 7.0-8.9h: aRR 1.00, 9.0-9.9h: aRR 1.15 (0.74-1.77), ≥10.0h: aRR 1.77 (0.88-3.54). 
Sleep duration and all-cause mortality in women: <7h: aRR 0.90 (0.50-1.61), 7.0-8.9h: aRR 1.00, 9.0-9.9h: aRR 1.07 (0.58-1.95), ≥10.0h: aRR 0.40 (0.06-2.92). 
Poor sleep quality (waking up feeling bad) on all-cause mortality (Male): aRR 1.13 (0.60-2.12). 
Poor sleep quality (waking up feeling bad) on all-cause mortality (Female): aRR 2.03 (1.10-3.74). 
Kripke 2002 (53) Up for 6 years. All-cause mortality: 
77,640/1,116,936. 
Sleep duration and all-cause mortality in men: 3h: aHR 1.19 (0.96-1.47), 4h: aHR 1.17 (1.06-1.28), 5h: aHR 1.11 (1.05-1.18), 6h: aHR 1.08 (1.04-1.11), 7h: aHR 1.00 (ref), 8h: aHR 1.12 (1.09-1.15), 9h: aHR 1.34 (1.28-1.40), ≥10h: 
1.08 (1.01-1.16). 
Sleep duration and all-cause mortality in women: 3h: aHR 1.33 (1.08-1.64), 4h: aHR 1.11 (1.01-1.22), 5h: aHR 1.07 (1.01-1.13), 6h: 1.07 (1.03-1.11), 7h: aHR 1.00 (ref), 8h: aHR 1.13 (1.09-1.16), 9h: 1.23 (1.17-1.28), ≥10 aHR 1.41 
(1.34-1.50). 
Lan 2007 (54) 8 years. All-cause mortality: 1,338/3,079. 
CVD mortality: 379/3,079. 
Sleep duration and all-cause mortality in men: <7h: aHR 0.98 (0.76-1.25), 7h: aHR 1.00, 8h: aHR 1.09 (0.89-1.33), 9h: aHR 1.14 (0.91-1.42), ≥10h: aHR 1.51 (1.19-1.92). 
Sleep duration and all-cause mortality in women: <7h: aHR 1.14 (0.77-1.67), 7h: aHR 1.00, 8h: aHR 1.36 (1.01-1.84), 9h: aHR 1.86 (1.36-2.53), ≥10h: aHR 2.06 (1.50-2.83). 
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Sleep duration and CVD mortality in men: <7h: aHR 0.91 (0.53-1.57), 7h: aHR 1.00, 8h: aHR 1.40 (0.93-2.10) 9h: aHR 1.26 (0.80-1.98), ≥10h: aHR 1.81 (1.13-2.89). 
Sleep duration and CVD mortality in women: <7h: aHR 1.07 (0.54-2.15), 7h: aHR 1.00, 8h: aHR 1.77 (1.05-2.98), 9h: aHR 1.75 (1.00-3.07), ≥10h: aHR 1.85 (1.04-3.27). 
Lee 2014 (55) 61.7 months. All-cause mortality: 297/3,427. Night time sleep duration ≥10h and mortality in men: aHR 1.75 (1.09-2.81).  
Night time sleep duration ≥10h and mortality in women: aHR 2.88 (1.01-8.18). 
Lee 2017 (56) 4.7 years. All-cause mortality: 72/937. Sleep duration and all-cause mortality: <6h: aHR 1.21 (0.67-2.17), 6-7h: aHR 1.00, ≥8h: aHR 2.11 (1.19-3.76). 
Leng 2015 (9) 9.5 years. Stroke 346/9,692. Sleep duration and stroke: <6h: aHR 1.18 (0.91-1.53), 6-8h: aHR 1.00, >8h: aHR 1.46 (1.08-1.98). 
Sleep duration and stroke in men: <6h: aHR 1.08 (0.75-1.57), 6-8h: aHR 1.00, >8h: aHR: 1.21 (0.80-1.82). 
Sleep duration and stroke in women: <6h: aHR 1.25 (10.86-1.83), 6-8h: aHR 1.00, >8h: aHR: 1.80 (1.13-2.85). 
Li 2013 (57) 7 years. All-cause mortality: 312/12,489. Sleep duration and all-cause mortality in men: <5h: aHR 1.44 (0.65-3.19), 6h: aHR 0.86 (0.50-1.48), 7h: aHR1.00, 8h: aHR 1.05 (0.72-1.53), >9h: aHR 1.70 (1.07-2.70). 
Sleep duration and all-cause mortality in women: <5h: aHR 1.01 (0.42-2.39), 6h: aHR 1.31 (0.78-2.21), 7h: aHR 1.00, 8h: aHR 1.01 (0.63-1.60), >9h: aHR 1.85 (1.09-3.13). 
Sleep duration and CVD mortality in men: <5h: aHR 1.57 (0.35-7.15), 6h: aHR 0.60 (0.17-2.15), 7h: aHR 1.00, 8h: aHR 1.04 (0.49-2.21), >9h: aHR 2.73 (1.22-6.11). 
Sleep duration and CVD mortality in women: <5h: aHR 0.80 (0.18-3.47), 6h: aHR 0.91 (0.38-2.23), 7h: aHR 1.00, 8h: aHR 1.13 (0.57-2.23), >9h: aHR 1.72 (0.76-3.89). 
Liu 2014 (58) Over 20 years. CHD: 491/3,381. Sleep duration and CHD: ≤6h: aHR 1.29 (1.03-1.61), 7-8h: aHR 1.00, ≥9h: aHR 1.13 (0.81-1.58). 
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Table 3: Study cohort, follow up and results for studies with authors M-Z. 
Study ID Follow up duration Outcomes and crude rate of 
outcomes 
Results 
Magee 2011 (59) Unclear. Stroke 6,541/218,155. Heart 
disease 25,669/218,155.  
Sleep duration and stroke: <6h: aOR 1.54 (1.36-1.75), 6h: aOR 1.25 (1.14-1.38), 7h: aOR 1.00, 8h: aOR 1.08 (1.01-1.17), ≥9h: 1.50 (1.38-1.62).  
Sleep duration and heart disease: <6h: aOR 1.23 (1.15-1.33), 6h: aOR 1.11 (1.06-1.17), 7h: aOR 1.00, 8h: aOR 1.01 (0.97-1.05), ≥9h: aOR 1.14 (1.09-1.19). 
 
Magee 2013 (60) 2.8 years. All-cause mortality 
8,782/227,815. 
Sleep duration and all-cause mortality: <6h: aHR 1.13 (1.01-1.25), 6h: aHR 0.99 (0.91-1.06), 7h: aHR 1.00, 8h: aHR 1.02 (0.96-1.08), 9h: aHR 1.04 (0.96-1.12), >10h: aHR 1.26 (1.16-1.36). 
Mallon 2002 (61) 12 years. All-cause mortality 266/2,663. 
Coronary artery disease 
mortality: 91/2,663. 
Sleep duration and all-cause mortality in men: <6h: aRR 1.1 (0.6-7.0), 7-8h: aRR 1.00, >8h: aRR 2.0 (1.2-3.2). 
Sleep duration and all-cause mortality in women: <6h: aRR 1.0 (0.6-1.8), 7-8h: aRR 1.00, >8h: aRR 1.3 (0.6-2.6). 
Sleep duration and coronary artery disease mortality in men: <6h: aRR 0.7 (0.3-1.7), 7-8h: aRR 1.00, >8h: aRR 2.2 (1.0-4.4). 
Sleep duration and coronary artery disease mortality in women: <6h: aRR 1.2 (0.4-4.2), 7-8h: aRR 1.00, >8h: aRR 0.7 (0.1-5.2). 
Poor sleep quality (difficulty maintaining sleep) and all-cause mortality in men: aRR 1.4 (1.1-1.9). 
Poor sleep quality (difficulty maintaining sleep) and coronary artery disease mortality in men: aRR 1.2 (0.7-1.9). 
Poor sleep quality (difficulty maintaining sleep) and all-cause mortality in women: aRR 1.1 (0.7-1.7). 
Poor sleep quality (difficulty maintaining sleep) and coronary artery disease mortality in women: aRR 1.1 (0.5-2.9). 
Martin 2011 (62) 1 year. All-cause mortality: 57/245. Sleep quality (high PQSI-7 day score) and all-cause mortality: aHR 1.12 (1.04-1.21). 
Meisinger 2007 (63) Unclear. Acute coronary event: 
295/6,896. 
Sleep duration and acute coronary event in men: ≤5h: aHR 1.13 (0.66-1.92), 6h: aHR 1.05 (0.71-1.55), 7h: aHR 1.22 (0.92-1.61), 8h: aHR 1.00 (reference), ≥9h: aHR 1.07 (0.75-1.53). 
Sleep duration and acute coronary event in women: ≤5h: aHR 2.98 (1.48-6.03), 6h: aHR 1.05 (0.49-2.27), 7h: aHR 1.34 (0.75-2.40), 8h: aHR 1.00 (reference), ≥9h: aHR 1.40 (0.74-2.64). 
Poor sleep quality (difficulty maintaining sleep) and acute coronary events in men: aHR 1.12 (0.84-1.48). 
Poor sleep qualtiy (difficulty maintaining sleep) and acute coronary events in women: aHR 1.53 (0.99-2.37). 
Mesas  2010 (64) 6.8 years. All-cause mortality: 897/3,820. Sleep duration and all-cause mortality: <5h: aOR 1.42 (1.04-1.96), 6h: aOR 1.23 (0.90-1.69), 7h: aOR 1.00, 8h: aOR 1.34 (1.02-1.76), 9h: aOR 1.48 (1.12-1.96), 10h: aOR 1.73 (1.30-2.29), >11h: aOR 1.66 (1.23-2.24). 
Pan 2014 (65) Up to 8 years. Stroke mortality: 1,381/63,257. Sleep duration and stroke deaths: <5h: aHR 1.25 (1.05-1.50), 6h: aHR 1.01 (0.87-1.18), 7h: aHR 1.00, 8h: aHR 1.09 (0.95-1.26), >9h: aHR 1.54 (1.28-1.85). 
Sleep duration and ischaemic or unspecified stroke deaths: <5h: aHR 1.37 (1.12-1.68), 6h: aHR 1.04 (0.87-1.24), 7h: aHR 1.00, 8h: aHR 1.14 (0.96-1.34), >9h: aHR 1.68 (1.36-2.06). 
Sleep duration and haemorrhagic stroke death: <5h: aHR 0.92 (0.62-1.36), 6h: aHR 0.91 (0.67-1.24), 7h: aHR 1.00, 8h: aHR 0.97 (0.73-1.29), >9h: aHR 1.14 (0.76-1.72). 
Patel 2004 (66) 14 years. All-cause mortality: 
5409/82,969. CVD mortality: 
1084/82,969. 
Sleep duration and all-cause mortality: <5h: aRR 1.08 (0.96-1.22), 6h: aRR 0.99 (0.92-1.06), 7h: aRR 1.00, 8h: aRR 1.11 (1.03-1.19), >9h: aRR 1.40 (1.25-1.55). Sleep duration and cardiovascular mortality: <5h: aRR 1.04 (0.79-1.35), 
6h: aRR 1.06 (0.91-1.25), 7h: aRR 1.00, 8h: aRR 1.12 (0.95-1.31), >9h: aRR 1.56 (1.25-1.96). 
Pollak 1990 (67) 3.5 years. All-cause mortality: 309/1,855. Incremental increase in hours of sleep and all-cause mortality in men: HR 0.96 (0.66-1.39). 
Incremental increase in hours of sleep and all-cause mortality in women: HR 1.11 (0.80-1.54). 
Qiu 2011 (68) 3 years. All-cause mortality: 
5,199/12,671. 
Sleep duration and all-cause mortality: <5h: aHR 0.97 (0.88-1.08), 6h: aHR 1.05 (0.95-1.16), 7h: aHR 1.00 (0.90-1.11), 9h: aHR 0.95 (0.83-1.07), >10h: aHR 1.09 (1.00-1.18). 
Sleep duration and all-cause mortality and men: <5h: aHR 1.17 (1.01-1.38), 6h: aHR 1.06 (0.91-1.25), 7h: aHR 1.17 (0.99-1.37), 9h: aHR 1.08 (0.89-1.31), >10h: aHR 1.22 (1.08-1.38). 
Sleep duration and all-cause mortality and women: <5h: aHR 0.85 (0.75-0.98), 6h: aHR 1.02 (0.90-1.15), 7h: aHR 0.88 (0.76-1.01), 9h: aHR 0.86 (0.72-1.02), >10h: aHR 1.00 (0.90-1.11). 
Sleep quality (poor vs. good) and all-cause mortality: aHR 0.91 (0.83-1.00). 
Sleep quality (poor vs. good) and all-cause mortality in men: aHR 1.11 (0.95-1.30). 
Sleep quality (poor vs. good) and all-cause mortality in women: aHR 0.81 (0.71-0.91). 
Qureshi 1997 (69) 10 years. Stroke 322/7,844. CHD: 
474/7,844. 
Sleep duration and risk for stroke: <6h: aOR 1.0 (0.7-1.5), 6-8h: aOR 1.0, >8h: aOR 1.5 (1.1-2.0). 
Sleep duration and CHD: <6h: aOR 1.3 (1.0-1.8), 6-8h: aOR 1.0, >8h: aOR 1.1 (0.8-1.5). 
Rhee 2012 (70) Up to 15 years. All-cause mortality: 990/14,533. Sleep duration and all-cause mortality: ≤5h: aHR 1.53 (1.11-2.12), 6-7h: aHR 1.04 (0.88-1.22), ≥8h: aHR 1.00. 
Rod 2014 (71) 22 years. All-cause mortality: 804/9,098. 
CVD mortality: 221/9,098. 
Sleep duration and all-cause mortality in men: ≤5h: aHR 1.11 (0.73-1.68), 6h: aHR 1.23 (1.01-1.50), 7h: aHR 1.00, 8h: aHR 1.18 (0.92-1.50), >9h: aHR 1.44 (0.59-3.50). 
Sleep duration and all-cause mortality in women: ≤5h: aHR 1.21 (0.76-1.91), 6h: aHR 1.14 (0.86-1.52), 7h: aHR 1.00, 8h: aHR 0.91 (0.63-1.30), >9h: aHR 1.48 (0.60-3.65). 
Sleep duration and CVD mortality: ≤6h: aHR 1.18 (0.87-1.63), 7-8h: aHR 1.00, >9h: aHR 1.61 (0.40-6.59). 
Poor sleep quality (disturbed sleep) and all-cause mortality in men: aHR 0.85 (0.62-1.16). 
Poor sleep quality (disturbed sleep) and all-cause mortality in women: aHR 1.03 (0.70-1.52). 
Poor sleep quality (disturbed sleep) and CVD mortality: aHR 1.04 (0.72-1.49). 
Ruigomez 1995 (72) 55.7 months. All-cause mortality 224/1,219. Sleep duration and all-cause mortality: <7h: aRR 0.83 (0.56-1.23), 7-9h: aRR 1.00, >9h: aRR 1.37 (0.89-2.11). 
Sleep duration and all-cause mortality in men: <7h: aRR 1.06 (0.61-1.83), 7-9h: aRR 1.00, >9h: 1.30 (0.71-2.38). 
Sleep duration and all-cause mortality in women: <7h: aRR 0.66 (0.37-1.16), 7-9h: aRR 1.00, >9h: 1.46 (0.79-2.70). 
Ruiter Petrov 2014 
(73) 
2 years. Stroke (at least 1 symptom): 
224/5,666. 
Sleep duration on stroke symptoms: <6h: aHR 1.47 (0.89-2.45), 6h: aHR 1.22 (0.82-1.81), 7h: aHR 1.00, 8h: aHR 1.30 (0.92-1.83), ≥9h: aHR 1.42 (0.82-2.45). 
Sands-Lincoln 2013 
(74) 
10.3 years. CVD events: 7,257/86,329. Sleep duration and CVD: ≤5h: aHR 1.06 (0.96-1.16), 6h: aHR 1.00 (0.95-1.06), 7-8h: aHR 1.00, 9h: aHR 0.95 (0.83-1.08), ≥10h: aHR 1.23 (0.89-1.70).  
Sleep duration and CHD: ≤5h: aHR 1.08 (0.96-1.20), 6h: aHR 1.00 (0.94-1.07), 7-8h: aHR 1.00, 9h: aHR 0.93 (0.80-1.08), ≥10h: aHR 1.33 (0.94-1.88).   
Shankar 2008 (75) 13 years. CHD mortality: 1,416/58,044. Sleep duration and CHD mortality: ≤5h: aRR 1.57 (1.32-1.88), 6h: aRR 1.13 (0.98-1.31), 7h: aRR 1.00, 8h: aRR 1.12 (0.97-1.29), ≥9h: aRR 1.79 (1.48-2.17). 
Song 2016 (76) 7.9 years. Stroke: 3,135/95,023. Sleep duration and stroke: <6h: aHR 0.92 (0.81-1.05), 6-8h: aHR 1.00, >8h: aHR 1.29 (1.01-1.64). 
Sleep duration and stroke in men: <6h: aHR 0.90 (0.78-1.03), 6-8h: aHR 1.00, >8h: aHR 1.24 (0.96-1.60). 
Sleep duration and stroke in women: <6h: aHR 1.09 (0.75-1.60), 6-8h: aHR 1.00, >8h: aHR 1.91 (0.98-3.74). 
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Stone 2009 (77) Up to 4.1 years. All-cause mortality: 793/6,107. Sleep duration and all-cause mortality in men: <5h: RH 1.2 (0.8-1.8), 7-8h: RH 1.00. 
Sleep duration and all-cause mortality in women: <5h: RH 1.8 (1.3-2.5), 7-8h: RH 1.00. 
 
Strand 2016 (78) 9.7 years. CHD mortality: 711/392,164. Sleep duration and CHD mortality: <4h: aHR 1.36 (0.88-2.10), 4-6h: aHR 1.03 (0.85-1.24), 6-8h: aHR 1.00, <8h: aHR 1.28 (1.05-1.56). 
Sleep duration and CHD mortality in men: <4h: aHR 1.03 (0.53-2.00), 4-6h: aHR 1.06 (0.85-1.32), 6-8h: aHR 1.00, <8h: aHR 1.11 (0.88-1.41). 
Sleep duration and CHD mortality in women: <4h: aHR 1.84 (1.03 -3.29), 4-6h: aHR 0.99 (0.72-1.37), 6-8h: aHR 1.00, <8h: aHR 1.81 (1.28-2.56). 
Difficulty getting to sleep and CHD mortality: aHR 1.01 (0.80-1.26). 
Suzuki 2009 (11) 6 years. All-cause mortality: 
1,004/14,001. CVD mortality: 
310/14,001. 
Sleep duration and all-cause mortality: ≤5h: aHR 0.92 (0.66-1.28), 6h: aHR 1.06 (0.80-1.39), 7h: aHR 1.00, 8h: aHR1.36 (1.09-1.70), 9h: aHR 1.41 (1.05-1.90), ≥10h: aHR 1.96 (1.49-2.57). 
Sleep duration and all-cause mortality in men: ≤5h: aHR 1.08 (0.72-1.61), 6h: aHR 1.05 (0.75-1.47), 7h: aHR 1.00, 8h: aHR 1.36 (1.04-1.78), 9h: aHR 1.52 (1.08-2.15), ≥10h: aHR 1.86 (1.34-2.56). 
Sleep duration and all-cause mortality in women: ≤5h: aHR 0.71 (0.39-1.29), 6h: aHR 1.08 (0.67-1.74), 7h: aHR 1.00, 8h: aHR 1.39 (0.92-2.09), 9h: aHR 1.15 (0.64-2.09), ≥10h: aHR 2.27 (1.37-3.76). 
Sleep duration and CVD mortality: ≤5h: aHR 1.10 (0.62-1.93), 6h: aHR 0.85 (0.50-1.45), 7h: aHR 1.00, 8h: aHR 1.52 (1.01-2.29). 9h: aHR 1.55 (0.91-2.63), ≥10h: aHR 1.95 (1.18-3.21). 
Sleep duration and CVD mortality in men: ≤5h: aHR 0.97 (0.46-2.05), 6h: aHR 0.75 (0.38-1.48), 7h: aHR 1.00, 8h: aHR 1.05 (0.63-1.75). 9h: aHR 1.26 (0.65-2.45), ≥10h: aHR 1.71 (0.94-3.11). 
Sleep duration and CVD mortality in women: ≤5h: aHR 1.48 (0.59-3.67), 6h: aHR 1.08 (0.44-2.66), 7h: aHR 1.00, 8h: aHR 2.83 (1.39-5.76). 9h: aHR 2.32 (0.93-5.77), ≥10h: aHR 2.31 (0.91-5.82). 
Poor sleep quality (frequent awakening) and all-cause mortality: aHR 0.99 (0.83-1.18). 
Poor sleep quality (frequent awakening) and all-cause mortality in men: aHR 1.00 (0.81-1.24). 
Poor sleep quality (frequent awakening) and all-cause mortality in women: aHR 0.96 (0.69-1.31). 
Poor sleep quality (frequent awakening) and CVD mortality: aHR 0.91 (0.66-1.26). 
Poor sleep quality (frequent awakening) and CVD mortality in men: aHR 0.97 (0.64-1.48). 
Poor sleep quality (frequent awakening) and CVD mortality in women: aHR 0.81 (0.49-1.35). 
Tamakoshi 2004 (79) 9.9 years. All-cause mortality: 
11,071/104,010. 
Sleep duration and all-cause mortality in men: ≤4h: aRR 0.88 (0.44-1.78), 5h: aRR 1.07 (0.83-1.38), 6h: aRR 1.11 (0.95-1.28), 7h: aRR 1.00, 8h: aRR 1.19 (1.07-1.32), 9h: aRR 1.27 (1.08-1.48), ≥10h: aRR 1.75 (1.46-2.09). 
Sleep duration and all-cause mortality in women: ≤4h: aRR 1.83 (1.20-2.81), 5h: aRR 1.18 (0.90-1.53), 6h: aRR 1.17 (0.99-1.39), 7h: aRR 1.00, 8h: aRR 1.35 (1.17-1.56), 9h: aRR 1.57 (1.26-1.96), ≥10h: aRR 2.12 (1.67-2.68). 
Tsubono 1993 (80) 4 years. All-cause mortality: 207/4,318. Sleep duration and all-cause mortality: ≤6h: aRR 1.26 (0.81-1.97), 7-8h: aRR 1.00, ≥9h: aRR 1.58 (1.16-2.15). 
Tu 2012 (81)  4 years. Unclear. Sleep duration and CHD in women: ≤4h: aOR 1.46 (1.26-1.70), 5h: aOR 1.28 (1.15-1.43), 6h: aOR 1.11 (1.02-1.21), 7h: aOR 1.00, 8h: aOR 0.95 (0.86-1.03), 9h: aOR 1.07 (0.92-1.25), ≥10h: aOR 1.41 (1.19-1.67). 
Sleep duration and stroke in women: ≤4h: aOR 1.75 (1.49-2.07), 5h: aOR 1.37 (1.21-1.55), 6h: aOR 1.16 (1.05-1.29), 7h: aOR 1.00, 8h: aOR 1.05 (0.94-1.17), 9h: aOR 1.07 (0.89-1.29), ≥10h: aOR 1.88 (1.56-2.27). 
Twig 2016 (82) 6.4 years. Coronary artery disease 
92/26,023. 
Poor sleep quality (highest vs lowest quartile) and coronary artery disease: aHR 2.38 (1.37-4.11). 
Von Ruesten 2012 
(83) 
8 years. Stroke 169/23,620. MI 
197/23,620. 
Sleep duration and MI: <6h: aHR 1.44 (0.85-2.43) 6h: aHR 0.80 (0.53-1.20), 7h: aHR 1.00, 8h: aHR 0.82 (0.56-1.19), ≥9h: aHR 0.89 (0.54-1.49). 
Sleep duration and strokes: <6h: aHR 2.06 (1.18-3.59), 6h: aHR 1.13 (0.72-1.77), 7h: aHR 1.00, 8h: aHR 1.16 (0.77-1.73), ≥9h: aHR 1.65 (1.00-2.73). 
Wang 2016 (84) 3.98 years MI: 423/101,510. All-cause 
mortality: 1,793/101,510. 
Sleep duration and MI: ≤5h: aHR 0.89 (0.60-1.30), 6h: aHR 0.84 (0.61-1.16), 7h: aHR 1.00, 8h: aHR 0.86 (0.66-1.13), ≥9h: aHR 1.12 (0.58-2.16).   
Sleep duration and all-cause mortality: ≤5h: aHR 1.23 (1.03-1.80), 6h: aHR 1.95 (0.81-1.12), 7h: aHR 1.00, 8h: aHR 1.06 (0.92-1.20), ≥9h: aHR 1.65 (1.22-2.22).   
Werle 2011 (85) 9 year. All-cause mortality: 141/187. CV 
mortality: 56/187. 
Incremental increase in hours of sleep and all-cause mortality: aHR 0.95 (0.89-1.02). 
Incremental increase in hours of sleep and CV mortality: aHR 0.83 (0.73-0.95). 
Westerlund 2013 (8) 13 year. CVD mortality: 857/41,192. 
Stroke: 1,685/41,192. MI: 
1,908/41,192. 
Sleep duration and CVD mortality: ≤5h: aHR 1.11 (0.76-1.64), 6h: aHR 1.17 (0.88-1.55), 7h: aHR 1.00, ≥8h: aHR 1.12 (0.85-1.47). Sleep duration and CVD: ≤5h: aHR 1.05 (0.88-1.26), 6h: aHR 0.97 (0.86-1.09), 7h: aHR 1.00, ≥8h: aHR 
1.00 (0.89-1.13). 
Sleep duration and stroke: ≤5h: aHR 1.05 (0.80-1.37), 6h: aHR 0.95 (0.79-1.14), 7h: aHR 1.00, ≥8h: aHR 0.87 (0.72-1.04). 
Sleep duration and MI: ≤5h: aHR 1.19 (0.92-1.55), 6h: aHR 1.05 (0.88-1.25), 7h: aHR 1.00, ≥8h: aHR 1.19 (1.00-1.41). 
Poor sleep quality (difficulty maintaining sleep) and CVD mortality: mostly/always aHR 0.97 (0.77-1.20). 
Wingard 1983 (86) 9 year. All-cause mortality: 369/6,928. Sleep duration and all-cause mortality in men: ≤6h: 52/352, 7-8h: 142/1735, ≥9h: 15/132. 
Sleep duration and all-cause mortality in women: ≤6h: 35/386, 7-8h: 107/1902, ≥9h: 17/200. 
Xiao 2014 (87) 14 years. All-cause mortality: 
44,100/239,896. CVD mortality: 
11,635/239,896. 
Sleep duration and all-cause mortality: <5h: aRR 1.16 (1.11-1.26), 5-6h: aRR 1.04 (1.02-1.06), 7-8h: aRR 1.00, ≥9h:aRR 1.11 (1.06-1.19). 
Sleep duration and CVD mortality: <5h: aRR 1.25 (1.13-1.38), 5-6h: aRR 1.06 (1.02-1.10), 7-8h: aRR 1.00, ≥9h: aRR 1.07 (0.97-1.17). 
Yeo 2013 (88) 9 years. All-cause mortality: 
1,580/13,164. CVD mortality: 
363/13,164. 
Sleep duration and all-cause mortality: ≤5h: aHR 1.21 (1.03-1.41), 6h: aHR 1.10 (0.95-1.27), 7h: aHR 1.00, 8h: aHR 1.03 (0.89-1.19), 9h: aHR 1.36 (1.11-1.67), ≥10h: aHR1.36 (1.07-1.72). 
Sleep duration on CVD mortality: ≤5h: aHR 1.40 (1.02-1.93), 6h: aHR 1.25 (0.92-1.69), 7h: aHR 1.00, 8h: aHR 1.04 (0.76-1.42), 9h: aHR 1.26 (0.81-1.96), ≥10h: aHR 1.37 (0.82-2.29). 
Zawisza 2015 (89) 10.8 years. All-cause mortality 2,093/2,449. Incremental increase in hours of sleep and all-cause mortality: aHR 1.04 (1.003-1.075). 
Zuubier 2015 (90) 7.3 years. All-cause mortality: 154/1,734. Sleep duration and all-cause mortality: <6h: aHR 1.12 (0.77-1.65), 6-7.5h: aHR 1.00, ≥7.5 h: 1.18 (0.70-1.98). 
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Figure 1: Flow diagram of study inclusion 
 
31 
 
Figure 2: Sleep duration and risk of all-cause mortality with linear and cubic splines 
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Figure 3: Linear models for adverse cardiovascular events 
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